SCHEMBL6029587

SCHEMBL6029587

CCCCCCCCCCCCc1cc(C(=O)O)c(NC(=O)OCCCCCCCC)s1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.54
CSNK2A2 P19784 3/20 0.47
CSNK2A1 P68400 3/20 0.47
ALDH1A1 P00352 4/20 0.46
RXFP1 Q9HBX9 1/20 0.45
EPHX1 P07099 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
GRIN2C Q14957 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
GAA P10253 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40
GLS O94925 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6031411 1.00 HSD17B10 (0.54) HSD17B10CSNK2A2CSNK2A1ALDH1A1RXFP1
SCHEMBL6030418 1.00 HSD17B10 (0.54) HSD17B10CSNK2A2CSNK2A1ALDH1A1RXFP1
SCHEMBL6031306 1.00 HSD17B10 (0.54) HSD17B10CSNK2A2CSNK2A1ALDH1A1RXFP1
SCHEMBL6031638 1.00 HSD17B10 (0.54) HSD17B10CSNK2A2CSNK2A1ALDH1A1RXFP1
SCHEMBL6031439 1.00 HSD17B10 (0.54) HSD17B10CSNK2A2CSNK2A1ALDH1A1RXFP1
SCHEMBL6031060 1.00 HSD17B10 (0.54) HSD17B10CSNK2A2CSNK2A1ALDH1A1RXFP1
SCHEMBL6031509 0.97 HSD17B10 (0.54) HSD17B10CSNK2A2CSNK2A1ALDH1A1RXFP1
SCHEMBL6031229 0.93 HSD17B10 (0.55) HSD17B10CSNK2A2CSNK2A1ALDH1A1RXFP1
SCHEMBL6031150 0.92 GAA (0.50) HSD17B10CSNK2A2CSNK2A1SMN1; SMN2GAA
SCHEMBL6029701 0.92 GAA (0.50) HSD17B10CSNK2A2CSNK2A1SMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7064122-B2 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2006-06-20 US disclosed
EP-1467978-A4 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARM INC (US) 2005-11-02 EP disclosed
EP-1467978-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI Pharmaceuticals, Inc. (US) 2004-10-20 EP disclosed
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. 2003-10-16 US disclosed
WO-2003053944-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARMACEUTICALS, INC. (US) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use PNLIP, LIPC, CEL HSD17B10 126/4885CSNK2A2 1345/4885CSNK2A1 1181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.